-+ 0.00%
-+ 0.00%
-+ 0.00%

Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer

Barchart·11/02/2026 07:25:00
Listen to the news

SHANGHAI and NANTONG, China, Nov. 2, 2026 /PRNewswire/ -- Ractigen Therapeutics, a leading clinical-stage biopharmaceutical company developing innovative small activating RNA (saRNA) therapeutics, today announced the official initiation of its multi-center Phase II clinical trial (Study RAG010201) of RAG-01 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) in China, marked by a clinical site initiation meeting held at Fudan University Shanghai Cancer Center (FUSCC).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.